Tech Session II: Nanomedicine and Nanoscale Delivery (Focus: Imaging)
uSPIO-5D3-DM1 Nano-conjugates as Optical-MRI Theranostics for PSMA-Positive Prostate Cancer Therapy
Tuesday, July 15, 2025
3:05 PM – 3:16 PM EDT
Introduction: Prostate cancer (PC) is one of the most widely diagnosed malignancies among men worldwide.[1-2] Almost all PCs eventually become insensitive to ADT and progress rapidly to the incurable metastatic castration-resistant PC (mCRPC).[3] Prostate-specific membrane antigen (PSMA) is overexpressed in most PCs (>95%).[4] The ultrasmall superparamagnetic iron oxide (uSPIO) nanoparticle-based image-guided and targeted drug delivery systems combine active and passive targeting properties and diagnosis and therapy. This strategy enhances therapeutic efficacy with minimal systemic toxicities.
Learning Objectives:
At the completion of this activity, participants will know
Upon completion, participant will be able to learn a novel MRI-theranostic drug delivery strategy.
Upon completion, participant will be able to learn novel in vitro and in vivo imaging techniques.
Upon completion, participant will be able to develop new collaborations.
